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Abstract The objective of this study was to assess patient
satisfaction with acute treatment of migraine with frova-
triptan or rizatriptan by preference questionnaire. 148
subjects with a history of migraine with or without aura
(IHS 2004 criteria), with at least one migraine attack per
month in the preceding 6 months, were enrolled and ran-
domized to frovatriptan 2.5 mg or rizatriptan 10 mg
treating 1–3 attacks. The study had a multicenter, ran-
domized, double-blind, cross-over design, with treatment
periods lasting\3 months. At the end of the study, patients
assigned preference to one of the treatments using a
questionnaire with a score from 0 to 5 (primary endpoint).
Secondary endpoints were pain-free and pain relief epi-
sodes at 2 h, and recurrent and sustained pain-free episodes
within 48 h. 104 of the 125 patients (83%, intention-
to-treat population) expressed a preference for a triptan.
The average preference score was not signiﬁcantly differ-
ent between frovatriptan (2.9 ± 1.3) and rizatriptan
(3.2 ± 1.1). The rates of pain-free (33% frovatriptan vs.
39% rizatriptan) and pain relief (55 vs. 62%) episodes at
2 h were not signiﬁcantly different between the two treat-
ments. The rate of recurrent episodes was signiﬁcantly
(p\0.001) lower under frovatriptan (21 vs. 43% riza-
triptan). No signiﬁcant differences were observed in
sustained pain-free episodes (26% frovatriptan vs. 22%
rizatriptan). The number of patients with adverse events
was not signiﬁcantly different between rizatriptan (34) and
frovatriptan (25, p = NS). The results suggest that frova-
triptan has a similar efﬁcacy to rizatriptan, but a more
prolonged duration of action.
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Introduction
Migraine is a common, chronic, neurovascular disorder,
typically characterized by recurrent disabling attacks of
severe headache, autonomic nervous system dysfunction,
and in up to a third of patients, neurological aura symptoms
[1]. The triptans, selective serotonin 5-HT1B/1D agonists,
are very effective acute migraine drugs [2]. The early
success of sumatriptan, the parent drug of this class [3], has
prompted the development of other triptan compounds,
trying to optimize efﬁcacy and safety in treatment of
migraine.
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DOI 10.1007/s10194-010-0243-yFrovatriptan is an antimigraine agent of the triptan class,
developed in order to provide a triptan with a clinical
potential for a long duration of action and a low likelihood
of side effects and drug interactions [4–6]. Randomized
placebo-controlled clinical studies and post-marketing
surveys showed that most patients with migraine reported
signiﬁcantly improved effectiveness and tolerability ratings
with frovatriptan versus placebo or previous acute thera-
pies, including triptans, analgesics, and non-steroidal anti-
inﬂammatory drugs [7, 8].
It is widely agreed that well-designed, double-blind,
randomized controlled trials that directly compare two or
more triptans provide the best clinical evidence for the use
of these drugs. Such trials are useful if they compare sev-
eral well-standardized effectiveness measures, if they cover
all available agents and doses, and if they assess adverse
events, enabling the reader to judge the ‘‘trade-offs’’
between the compared drugs [9]. However, with the only
exception of a head-to-head randomized trial versus
sumatriptan [10], frovatriptan efﬁcacy had never been
tested in comparative trials with other triptans. For this
reason a study was setup to compare efﬁcacy and safety of
frovatriptan versus rizatriptan, the triptan known to provide
consistent relief of migraine attacks and usually preferred
over other treatments because of its speed of relief [11, 12].
The study had been designed to assess efﬁcacy by
considering patient’s preference to treatment [13, 14] and
also by analyzing traditional migraine treatment endpoints.
Methods
Study population
The study included subjects of male or female gender,
18–65 years old, with a current history of migraine with or
without aura, according to International Headache Society
(IHS) 2004 criteria, and with at least one, but no more than
six migraine attacks per month for 6 months prior to
entering the study [15].
Patients could not be enrolled in the study in case of: (a)
uncontrolled hypertension; (b) ischemic heart disease; (c)
cardiac arrhythmias or symptomatic Wolff–Parkinson–
White syndrome; (d) previous stroke or transient ischemic
attack; (e) severe liver or renal impairment; (f) any other
severe or disabling medical condition; (g) history of alcohol
or analgesic or psychotropic drug abuse; (h) known
hypersensitivity to study drugs; (i) previously demonstrated
inadequate response to at least two triptans; (j) current use
of propranolol or ergothamine (and its derivatives) as a
prophylactic agent; (k) current use or use in the previous
2 weeks of MAO-inhibitors; (l) use of either test medication
to treat any one of the last three episodes of migraine; and
(m) other headaches that have been lasting for more than
6 days. Pregnant women and breast-feeding mothers were
excluded as well, while women with childbearing potential
but not practicing an effective method of birth control were
to be submitted to a pregnancy test, if clinically indicated.
Written informed consent was obtained from all patients
prior to their inclusion into the study. The study was
approved by the Independent Institutional Review Boards
of the study centers.
Study design
This was a multicenter, randomized, double-blind, cross-
over study, including 15 centers across Italy (Appendix).
Each patient received frovatriptan 2.5 mg or rizatriptan
10 mg in a balanced computer-generated randomized
sequence (1:1), where frovatriptan had to be followed by
rizatriptan or viceversa. After treating three episodes of
migraine in no more than 3 months with the ﬁrst treatment,
the patient had to switch to the other treatment. Random-
ization was done by blocks of 4. Blindness was ensured by
the overencapsulation technique, i.e., by inserting study
drug tablets in capsules. After treating three episodes of
migraine in no more than 3 months with the second treat-
ment, each patient was asked to assign preference to one of
the treatments according to a questionnaire with a prefer-
ence score graded from 0 to 5.
The study involved three visits and each patient’s par-
ticipation time in the study had not to exceed 6 months
from randomization. Subjects having no migraine episodes
during one of the two observation periods were excluded
from the study.
During the randomization visit, after signing written
informed consent, subjects provided medical, medication,
and migraine history. Physical and neurological examina-
tions and pregnancy test (if appropriate) were performed.
Blood pressure and heart rate were measured for all
subjects. The degree of migraine-associated disability
(MIDAS questionnaire) was also completed. At the end of
the visit a headache diary documenting characteristics of
headache pain and associated symptoms was dispensed
with study medication. Subjects were instructed to treat at
least three migraine episodes occurring in no more than
3 months and to come for the second visit. On this occasion
use of concomitant medications and occurrence of adverse
events (from diary) were checked, blood pressure and heart
rate were recorded, and a pregnancy test performed, if
deemed necessary. The same procedures were carried out
at the end of the second study treatment period or at the
early withdrawal visit, together with the administration of
the patient’s preference questionnaire.
Patients were instructed to take one dose of study medi-
cation as early as possible after the onset of migraine attack.
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123If insufﬁcient relief had been obtained after 2 h, patients
wereallowedtotakeaseconddoseofstudymedication,with
a maximum daily intake of two doses. In case of insufﬁcient
relief 1 h after the intake of the second dose of the study
medication, patients were allowed to take a rescue medica-
tion. Alternate rescue medication could not include triptans,
or contain ergotamine or its derivatives, or propranolol.
Data analysis
The primary study endpoint was the between-treatment
comparison of the direction and average strength of pref-
erence at the end of the study, measured on a scale from 0
(no preference) to 5 (strong preference) [14]. The rate of
patients expressing a preference and reason for preference
were also calculated. The preference scale and question-
naire are reported in Fig. 1 and Appendix 1 (Supplemen-
tary material).
The hypothesis was that a superiority of one treatment
against the other had to occur in the presence of a differ-
ence of ?1.0 with a standard deviation of 2.375. Consid-
ering a two-tailed test with a 0.05 signiﬁcance level and an
80.7% power, the estimated number of patients to be ran-
domized was 120 (including a 25% drop-outs), 60 for each
treatment group.
The intention-to-treat population, including all patients
who treated at least one attack in each treatment period and
completed the preference questionnaire, was the study
primary analysis population. The per-protocol population
consisted of all patients treating the three anticipated
migraine episodes in a maximum of 3 months during both
treatment periods and who expressed their preference at
study termination, with no protocol violations. This popu-
lation was used for conﬁrmatory analysis.
Secondary study endpoints were quantiﬁed according to
IHS Guidelines [15]. In summary, these endpoints were (a)
the number of pain-free episodes at 2 h (absence of
migraine episodes at 2 h after intake of one dose of study
drug), (b) recurrence, assessed as stated in the protocol, i.e.,
an episode of migraine occurring within 48 h from the
previous one, after a period without migraine, and also
more appropriately as an episode which is pain free at 2 h
and headache of any severity returns within 48 h, without
taking a second dose or a rescue medication; (c) the
number of sustained pain-free episodes within 48 h
(migraine attack which is pain free at 2 h, does not recur
and does not require the use of rescue medication within
48 h), (d) the number of pain relief episodes at 2 h (deﬁned
as a decrease in migraine intensity from severe or moderate
to mild or none). Consistency of response (responders in 2
and 3 out of 3 attacks) was assessed for the secondary
endpoints. An evaluation of the total amount of working
hours lost due to migraine attacks and the rate of occur-
rence of nausea, vomiting, photophobia, phonophobia, and
osmophobia 2, 4, 24, and 48 h after drug intake, were also
assessed.
Safety analysis was applied to all randomized patients,
by calculating the incidence of adverse events and changes
in vital signs during the study.
Continuous variables were summarized by computing
average values and standard deviation (SD), while cate-
gorical variables by computing the absolute value and the
frequency (as percentage). Preference scores were com-
pared between-treatment groups by analysis of variance.
Secondary endpoints were compared between groups by
generalized estimating equation analysis. Kaplan–Meyer
curves for cumulative hazard of recurrence over 48 h were
also drawn. p value refers to the statistical signiﬁcance
of between-treatment difference. The level of statistical
signiﬁcance was kept at 0.05 throughout the whole study.
Results
Baseline demographic and clinical data
Overall, 148 patients were screened and randomized to
active treatment. Of these patients, 129 completed the study
and 19 prematurely withdrew from the study because of
dissatisfaction to assigned treatment (n = 1), withdrawal of
consent (n = 6), failure to treat one episode of migraine
(n = 6), occurrence of an adverse event (n = 2), protocol
violation (n = 1), deterioration of target disease symptoms
(n = 1), or other reasons (n = 2). A ﬂow diagram of the
patients throughout the study is reported in Fig. 2.
The intention-to-treat population consisted of 125
patients, while patients valid for per-protocol analysis were
96. Safety analysis was carried out in 137 patients.
Table 1 shows main demographic and clinical charac-
teristics of patients of the intention-to-treat. Most of the
subjects enrolled were females. No patients with migraine
with aura reported previous treatment with triptans. Similar
results were observed for the per-protocol population.
543210 1 2345
strong 
preference
no 
preference
strong 
preference
preference for the 
medication of the 
first period
preference for the 
medication of the 
second period
Fig. 1 Example of preference scoring. For details on the contents of
the preference questionnaire, please refer to Appendix 1 (Supple-
mentary material)
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123Primary end point
In the intention-to-treat population, the preference score
averaged to 2.9 ± 1.3 for frovatriptan and to 3.2 ± 1.1 for
rizatriptan (p = NS).
A total of 104 (83%) patients expressed a clear prefer-
ence for a triptan: 42 (38%) for frovatriptan and 40 (45%)
for rizatriptan (p = NS between treatments).
The reasons for preferring one triptan in the intention-
to-treat population were the rapid action (71% frovatriptan
PATIENTS SCREENED
N = 148
PATIENTS RANDOMIZED
N = 148
PATIENTS ASSIGNED   
TO GROUP:
Frovatriptan / Rizatriptan
N = 75
PATIENTS ASSIGNED    
TO GROUP:
Rizatriptan / Frovatriptan
N = 73
COMPLETED
N = 68
COMPLETED
N = 61
ITT Population
N = 65
ITT Population
N = 60
PP Population
N = 52
PP Population
N = 44
- Voluntary withdrawal of consent  (N = 2)
- Failure to treat 1 episode of migraine (N = 2)
- Deterioration of  target symptoms (N = 1)
- Dissatisfaction with the treatment assigned (N = 1)
- Other (N = 1)
Exclusion  from  ITT  Population:
- No attacks treated (N = 9)
- Preference Form not available (N = 4)
Exclusion  from  ITT  Population:
- No attacks treated (N = 2)
- Preference Form not available (N = 8)
Exclusion  from  PP  Population:
- Less than 3 attacks/period (N = 4)
- Wrong use of rescue medication (N = 9)
Exclusion  from  PP  Population:
- Less than 3 attacks/period (N = 14)
- Wrong use of rescue medication (N = 2)
- Voluntary withdrawal of consent  (N = 4)
- Failure to treat 1 episode of migraine (N = 4)
- Adverse Event (N = 2)
- Serious protocol violation (N = 1)
- Other (N = 1)
Fig. 2 Flow diagram of participants throughout the study
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123vs. 66% rizatriptan), followed by reduction in migraine
severity (33 vs. 54%), complete analgesia (33 vs. 54%),
functional recovery (33 vs. 36%), and improved tolerability
(42 and 38%). No signiﬁcant differences were observed
between treatments. Additional preference results will be
published in details elsewhere. Results of analysis of the
per-protocol population did not differ from those of the
intention-to-treat group.
Secondary endpoints
Results of the analysis of secondary endpoints are sum-
marized in Table 2. In the intention-to-treat population, the
rates of pain-free (33% with frovatriptan vs. 39% with
rizatriptan) and pain relief episodes at 2 h (55% with
frovatriptan vs. 62% with rizatriptan) were not signiﬁcantly
(p = NS) different between the two treatments (Table 2).
Rate of recurrent episodes was signiﬁcantly lower under
frovatriptan, either when deﬁned according to the protocol
(22 vs. 32% rizatriptan; p\0.001) or to IHS indications
(21 vs. 43%; p\0.001). This was conﬁrmed by a signif-
icantly (p\0.05) lower cumulative hazard of recurrence
over the 48 h (Fig. 3).
Sustained pain-free episodes were also similar between
the two groups (26% frovatriptan vs. 22% rizatriptan;
p = NS) (Table 2). No difference was observed between
the intention-to-treat and the per-protocol population for
main secondary endpoints (Table 2).
Consistency of response for secondary endpoints resul-
ted statistically signiﬁcant in favor of frovatriptan for pain
relief at 2 h (Table 3).
Treatment with frovatriptan had also a positive impact
on the amount of working hours lost due to migraine
attacks, which was signiﬁcantly lower with this drug
(1.5 ± 3.1 h) than with rizatriptan (2.8 ± 9.4 h, p\0.05)
in the intention-to-treat population. Number of concomitant
medications was similar between the two study sequences
(130 for frovatriptan–rizatriptan sequence and 135 for ri-
zatriptan-frovatriptan sequence). Also use of second dose
and rescue medication, and severity of headache at the time
of study drug intake did not signiﬁcantly differ between
study groups (Table 4).
Both drugs gradually reduced migraine-related symp-
toms, with no differences between treatments (Fig. 4).
Safety
Safety analysis was carried out in 137 patients. Adverse
events were reported by 25 patients during treatment with
frovatriptan and by 34 patients during treatment with ri-
zatriptan (18.8 vs. 26.2% of treated patients,) for an overall
number of 158 adverse events (65 under frovatriptan and
93 under rizatriptan). Most of the events were of a mild or
moderate intensity, and no serious adverse events were
recorded during the study. No patients under Frovatriptan
prematurely withdrew from the study while two patients
under Rizatriptan did.
Side effects attributed to study treatment were 89
(56.3% of total events) and occurred in 13 patients during
frovatriptan and in 15 patients during rizatriptan treatment
(p = NS). As reported in Table 5 the number of drug-
related adverse events was slightly, but not signiﬁcantly,
greater under rizatriptan than frovatriptan.
Table 1 Demographic and clinical data of the 125 patients of the
intention-to-treat population and of the 96 patients of the per-protocol
population at the time of randomization
ITT
(n = 125)
PP
(n = 96)
Age (years, mean ± SD) 37 ± 93 7 ± 9
Females (n, %) 99 (79) 75 (78)
Height (cm, mean ± SD) 167 ± 9 167 ± 9
Weight (kg, mean ± SD) 64 ± 13 64 ± 13
Age at onset of migraine (years, mean ± SD) 16 ± 71 6 ± 7
Migraine attack duration[2 days (n, %) 26 (21) 14 (15)
MIDAS score (mean ± SD) 22 ± 15 21 ± 16
Migraine with aura (n, %) 4 (3) 3 (3)
Data are shown as mean (±SD), or absolute (n) and relative frequency
(%)
Table 2 Result for the secondary study endpoints
ITT (n = 125) p PP (n = 96) p
Frovatriptan Rizatriptan Frovatriptan Rizatriptan
Pain-free episodes at 2 h 117 (33) 141 (39) NS 107 (37) 116 (40) NS
Recurrent episodes (IHS) 25 (21) 61 (43) \0.001 21 (20) 40 (35) \0.05
Recurrent episodes (protocol) 77 (22) 117 (32) \0.001 61 (21) 91 (32) \0.01
Sustained pain-free episodes 92 (26) 80 (22) NS 86 (30) 76 (26) NS
Pain relief episodes at 2 h 155 (55) 166 (62) NS 129 (61) 134 (60) NS
Data are shown for the intention-to-treat and per-protocol population and reported as absolute (n) and relative (%) frequency. p refer to the
statistical signiﬁcance of the difference between the two treatment groups
J Headache Pain (2011) 12:219–226 223
123Treatment was accompanied by no relevant changes in
vital signs, ECG, or results of cardiovascular examination.
Discussion
In this direct comparative study of frovatriptan versus
rizatriptan in acute migraine, the two drugs showed a
similar efﬁcacy, but frovatriptan had a more sustained
analgesic effect. Our results were consistent for both the
intention-to-treat and per-protocol population.
Patient’s preference for one drug or the other did not
differ between the study treatments. Frovatriptan was
chosen mainly because of the rapid speed of action (71% of
patients), good tolerability (42% of patients), and reduction
in pain severity (33%). The fact that approximately 70% of
patients preferred frovatriptan for its rapid activity con-
ﬁrms what was recently reported in a long-term open label
study, namely that frovatriptan may provide a remarkably
fast and high headache response in more than one-third of
migraineurs, labeled as ‘‘rapid responders’’ [16].
A relevant result of our study is that recurrence rate
within 48 h were signiﬁcantly lower under frovatriptan
than under rizatriptan. These differences may be explained
by the different pharmacokinetics of the two drugs. Indeed,
earlier studies have shown that, due to its shorter time to
maximum concentration, rizatriptan tends to produce a
quicker onset of headache relief and a faster freedom from
pain than sumatriptan (the reference drug of the class),
zolmitriptan, and naratriptan [6, 17]. For this reason riza-
triptan is now widely regarded by many physicians as a
ﬁrst-line treatment option for the management of migraine
[17]. Conversely, frovatriptan has a time to maximum
concentration typically of 2 to 3 h, but the longest half-life
among triptans, greater 5-HT1B binding receptor potency,
and multiple pathways metabolism. These pharmacological
features might explain differences in clinical efﬁcacy
between the two drugs and why frovatriptan, unlike other
triptans, including rizatriptan, greatly reduced the risk of
migraine recurrence [18–21].
Though previous direct comparisons between frova-
triptan and rizatriptan are not available, our results are in
line with those of previous placebo-controlled studies
based on these two triptans [22, 23]. As far as frovatriptan
is regarded, in a review of ﬁve randomized, double-blind,
placebo-controlled studies, headache response rate at 2 h
(pain relief) for frovatriptan ranged between 38 and 40%
before placebo correction, while it was slightly higher in
our study (55%) [22]. In previous studies frovatriptan was
more effective than placebo in rendering patient pain free
at 2 (12% of patients) and 4 h (29% of patients) [4, 7]. The
additional ﬁnding of our study is that proportion of pain-
free episodes at 2 h was much higher than that observed in
Time (hour)
50 45 40 35 30 25 20 15 10 5 0
1,0
,9
,8
,7
,6
,5
,4
,3
,2
,1
0,0
Frovatriptan
Rizatriptan
p<0.05
ITT (n=125)
Fig. 3 Cumulative hazard of recurrence over the 48 h during
treatment with frovatriptan (continuous line) or rizatriptan (dashed
line), in the 125 patients of intention-to-treat population. Recurrence
was deﬁned according to protocol
Table 3 Result of consistency analysis for the secondary study
endpoints
ITT (n = 125) p
Frovatriptan Rizatriptan
Pain-free episodes at 2 h 88 (75) 108 (77) NS
Recurrent episodes (IHS) 13 (52) 31 (51) NS
Recurrent episodes (protocol) 49 (64) 85 (73) NS
Sustained pain-free episodes 61 (66) 57 (71) NS
Pain relief episodes at 2 h 132 (85) 127 (77) \0.05
Consistency of response was deﬁned as responders in 2 and 3 out of 3
attacks. Data are shown for the intention-to-treat population and
reported as absolute (n) and relative (%) frequency. p refer to the
statistical signiﬁcance of the difference between the two treatment
groups
Table 4 Migraine attacks with use of two or more doses, rescue
medication, and severity of headache at the time of drug intake
ITT (n = 125) p
Frovatriptan
(n = 357)
Rizatriptan
(n = 362)
Use of 2 doses of study medication 110 (31) 122 (34) NS
Use of[2 doses of study medication 67 (19) 74 (20) NS
Use of rescue medication 71 (20) 59 (16) NS
Severity of headache at study drug intake
Mild 76 (21) 93 (25) NS
Moderate 203 (57) 201 (56) NS
Severe 78 (22) 68 (19) NS
Data are shown for the intention-to-treat population and reported as
absolute (n) and relative (%) frequency. p refer to the statistical
signiﬁcance of the difference between the two treatment groups
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123previous placebo-controlled studies (33 vs. 9–14%).
Headache recurrence at 24 h averaged to 17% in a previous
meta-analysis [20]: in our study headache recurrence was
assessed more properly within the 48 h, as indicated by
IHS guidelines [15], and was signiﬁcantly less frequent
than under rizatriptan. This is in line with results of open
label naturalistic studies and meta-analyses of placebo-
controlled efﬁcacy studies, which suggest that in a real-
world setting frovatriptan is associated with a lower rate of
migraine recurrence than with other triptans [24]. Post-
marketing surveys also indicate that the long duration of
action of frovatriptan appears to confer other beneﬁts such
as greater patient satisfaction, with over 85–90% of
patients and physicians rating frovatriptan therapy as very
good or good, both in terms of efﬁcacy and tolerability
[8, 24].
The lower recurrence of headache after 48 h from drug
intake with frovatriptan seems to support indication of
frovatriptan for those patients requiring a prolonged dura-
tion of action, with a sustained effect. Pharmacokinetic
features of frovatriptan may make it suitable for patients
who need prophylaxis such as in menstrual-related migraine
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125 patients of the intention-to-
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Table 5 Distribution of
absolute numbers of drug-
related adverse events between
the two treatment groups in the
137 patients of the safety
analysis
Intensity All
(n = 137)
Frovatriptan (n = 133) Rizatriptan (n = 130)
Mild Moderate Severe Mild Moderate Severe
Asthenia 3 5 2 1 4 1 16
Somnolence 3 – – – 6 5 14
Dizziness 1 – – 2 4 1 8
Nausea or vomiting – – 3 – 1 – 4
Throat tightness 1 – – 2 2 3 8
Pain increase – 1 3 – – 2 6
Burning sensation to nose and forehead 1 1 3 – 1 – 6
Palpitation or tachycardia – – – 2 2 – 4
Sensation of being dazed 2 1 – – 1 – 4
Instability or imbalance – – – 1 3 – 4
Abdominal pain – – 1 – – – 1
Muscular or bone pain – 2 – – – – 2
Thoracic constriction – – – – 1 – 1
Tremor or shivers – – – 1 1 – 2
Other 1 2 3 – 2 1 9
Total adverse events 39 50 89
Total patients (%) 13 (9.8) 15 (11.5) 28 (20.4)
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123and for patients typically suffering from migraines of long
duration or with frequent recurrence [4, 25, 26]. In these
patients, early use of frovatriptan has been shown to be
associated with a greater beneﬁt [27]. Conversely, riza-
triptan may be useful for those patients requiring a rapid
pain relief. The prolonged analgesic effect of frovatriptan is
also reﬂected in a smaller number of working hours lost due
to migraine under treatment with these drugs.
In conclusion, our multicenter, randomized, double-
blind study suggests that frovatriptan and rizatriptan are
similarly preferred in migraineurs patients and share a
similar antimigraine efﬁcacy, though the former seems to
have a more prolonged and sustained analgesic effect.
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